PubMed Health⌕ Search

Biomedical subjects

H Maass

Publications and source records attributed to H Maass.

At least 73 records · Page 4Linked to original sources
PubMed1981

[Experimental and clinical aspects of hormone therapy in breast cancer (author's transl)].

This paper gives a review of the historical development of endocrine treatment procedures of breast cancer patients. Compared with the chemotherapy endocrine therapies have less side effects and are less expensive. On the other hand, the remission rates in unselected patients are in the range of 30% only. The determination of steroid hormone receptors at present is the best method for selection of the patients. The remission rates in patients with estrogen receptor positive tumors are 50-60%, with additionally progesterone receptor presence up to 77%. Patients lacking receptors in their tumor tissue have a little chance [5 (-10) %] of responding to an endocrine measure. This is true for ablative (ovariectomy, adrenalectomy, hypophysectomy) as well as for additive procedures (estrogens, androgens, antiestrogens).

Adrenalectomy↗
PubMed1981

[Hormonreceptors in the therapy concept of breast cancer (author's transl)].

The determination of hormone receptors in tumor tissue samples today is accepted as a necessary step with in a selective treatment plan for patients with breast cancer. The following way discussed our clinical knowledge about hormone receptors in breast cancer. Besides a therapy concept for metastatic breast cancer an adjuvant treatment trial for stage II breast cancer patients based on the estrogen receptor status will be presented.

Breast Neoplasms↗
PubMed1980

Estrogen receptor status and response to polychemotherapy in advanced breast cancer.

In a retrospective study, response to systemic polychemotherapy was analyzed in 72 female patients having advanced breast cancer and correlated with estrogen receptor (ER) status. Estrogen receptors were analyzed by agar-gel electrophoresis or uptake competition technique in tumor biopsy specimens derived from the primary tumor or from metastases. The borderline between positive and negative ER values was declared to be 20 fmol/mg tissue protein. Most of the patients have had an extramural review. We did not find statistically significant differences between the ER-positive (ER+), and ER-negative (ER-) groups in these characteristics: age; menopausal status; disease-free interval; dominant site of involvement. Chemotherapy regimens utilized in the two groups were comparable. According to criteria formulated by the European Organization on Research and Treatment of Cancer (EORTC), there is no evidence that response to chemotherapy is correlated with the presence or absence of estrogen receptor. Thirteen of 31 ER+ patients responded objectively to chemotherapy (42%) and 17 or 41 ER- patients gained such remission (41%). Given the retrospective nature of the data, this result should be interpreted cautiously. More clinical studies are warranted to determine whether response to cytotoxic agents is affected by ER status.

Age Factors↗
PubMed1980

The problem of nonresponding estrogen receptor-positive patients with advanced breast cancer.

Patients with advanced breast cancer and low or poor concentration of estrogen receptors in tumor biopsies have little chance of responding to endocrine therapy. This problem was seen in a group of nonresponding estrogen receptor-positive (ER+) patients. Some comments on possible explanations for this phenomenon are made and suggestions to overcome it are given.

Antineoplastic Agents↗
PubMed1978

[Epidemiology of mastocarcinoma (author's transl)].

Epidemiological examination of female patients with mastocarcinoma yields distinct differences in the rate of incidence among different groups of patients. In the industrial countries of the West, mastocarcinoma is 8 to 10 times more frequent than in the Far East and in some developing countries. In all groups under investigation, late primiparae are at an increased risk. Other risk factors are: previous familial history of mastocarcinoma, nulliparousness, women after a treated mastocarcinoma, as well as women with proliferating mastopathy. The setting up of risk groups enabled better on-target focussing of preliminary-care examinations.

Adult↗
PubMed1978

[Endocrinal and chemotherapy of the metastasising mastocarcinoma (author's transl)].

Treatment of the metastasising mastocarcinoma is based on endocrinal and cytostatic treatment methods arranged systematically in parallel and in series. With endocrinal therapy alone, remission rates of around 30% are achieved, whereas with polychemotherapy the remission rates are 50 to 60%. For a large proportion of the patients, the systematic application of both methods leads to definite increase in life expectancy at a tolerable quality of life level. The determination of steroid hormone receptors in the tumorous tissue allows better selection of the patients and hence better on-target therapy.

Antineoplastic Agents↗
PubMed1978

Some comments on the necessity of receptor determination in human breast cancer.

Estrogen receptors (ER's) were determined by agar gel electrophoresis in 105 human mammary tumor biopsies. Fifty-three tumor specimens revealed measurable amounts of receptor, and 64% of these patients showed an objective remission after endocrine treatment. If we also include cases with partial remission, previous response, and arrested growth but no actual remission, the benefit rate increases to 87%. The corresponding percentage in the ER-negative groups is 13%. In a retrospective study of 42 patients with human breast cancer, a correlation between ER finding and remission rate after chemotherapy was found. Of the ER-negative patients, 71% showed an objective remission after polychemotherapy, whereas only 43% of the ER-positive cases revealed such remission. The presented data are discussed with special regard to their clinical relevance.

Antineoplastic Agents↗
PubMed1977

Progesterone in the uterus. VII. Uptake of cortisol and incorporation of progesterone under simultaneous application of cortisol into rat uterus.

After injection of radioactively labelled cortisol, the distribution of the radioactivity in the subcellular fractions of the rat uterus (nuclei, mitochondria, microsomes and 105 000 X g supernatant) was studied. In all fractions, radioactivity was observed and maxima were found 10, 20 and 50 min. after injection of the labelled hormone. Radioactivity was measured in all subcellular fractions even 180 min. after application of labelled cortisol. Additionally, radiolabelled progesterone and unlabelled cortisol in the ratio 1:1 or 1:2 (moles:moles) were injected into the animals. Studying the uptake of labelled progesterone in the subcellular fractions of the uterine tissue, revealed that no competition of unlabelled cortisol could be observed 10, 20 and 50 min. after application of the hormone mixture, compared with the control experiments. The results of this study give evidence that the progesterone uptake into rat uterus is specific and cannot be influenced by unlabelled cortisol.

Animals↗
PubMed1977

Progesterone in the uterus. VIII. Uptake of corticosterone and incorporation of progesterone under concurrent injection of corticosterone into rat uterus.

A study of the subcellular distribution of radioactivity in rat uterus after injection of labelled corticosterone showed that the radioactivity was observed in all fractions from 5 min. to 120 min. A maximum uptake was observed 10 min. after application of the labelled steroid. Competitive uptake of radioactive progesterone and unlabelled corticosterone was assayed 10 min. after injection of the hormone mixture. The ratio between radioactive progesterone and unlabelled corticosterone was 1:1 and 1:2 (moles:moles), respectively. Compared with control experiments with rats which had received radioactive progesterone alone, the results gave evidence that progesterone found in all subcellular fractions and in the total homogenate was not depressed by unlabelled corticosterone. However, unlabelled progesterone reduced the tritiated progesterone in uterine tissue. This observation demonstrates that the uptake of progesterone by rat uterus is specific.

Animals↗
PubMed1977

Specific binding of estradiol and dihydrotestosterone in human mammary cancers.

Estrogen and dihydrotestosterone receptors were detected by agar gel electrophoresis in 224 human mammary tumor biopsies. Approximately half of the tumor specimens revealed measurable amounts of estradiol receptors, whereas only 20% contained dihydrotestosterone receptors. The average concentration of spare estrogetmenopausal than in the premenopausal group, but this was not found to be the case for androgen receptors. The findings presented are discussed with regard to the clinical relevance of multiple assays for various types of receptors in a single tumor.

Breast Neoplasms↗
PubMed1976

Progesterone in the uterus. VI. On the question of the in vitro progesterone metabolism in human endometrium and myometrium.

Human endometrial and myometrial tissue pieces were incubated with radioactively labeled progesterone in nutrient medium for 20 min., 1 hr and 2 hrs. The only compound extracted from the tissue pieces and the nutrient fluids was identified to be progesterone by TLC, chemical reactions and crystallization experiments. Radiometabolites could not be detected in the tissue pieces and in the nutrient fluids under the experimental conditions applied (10(-7) M 1,2-3H-progesterone in the incubation medium). This result is comparable with recent findings on the in vitro progesterone metabolism by rat uterine tissue.

Chromatography, Thin Layer↗